7 completed. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 2 | Completed 2 |
Follow MedImmune Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. MEDI2070, placebo - Crohn's Disease | Phase 2 | Completed | AstraZeneca | 121 | 2013-02-01 | 2021-05-26 |
| A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis Mavrilimumab 30 mg, Mavrilimumab 100 mg, Mavrilimumab 150 mg - Rheumatoid Arthritis | Phase 2 | Completed | MedImmune LLC | 420 | 2012-08-01 | 2016-09-27 |
| Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis tralokinumab, placebo - Ulcerative Colitis | Phase 2 | Completed | AstraZeneca | 147 | 2012-03-01 | 2016-04-05 |
| Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg - Asthma | Phase 2 | Completed | MedImmune LLC | 964 | 2010-12-01 | 2016-11-17 |
| A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects CAT-354, CAT 354 - Healthy | Phase 1 | Completed | MedImmune LLC | 30 | 2010-04-01 | 2012-08-30 |
| A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis Mavrilimumab 10 mg, Mavrilimumab 30 mg, Mavrilimumab 50 mg - Rheumatoid Arthritis | Phase 2 | Completed | MedImmune LLC | 516 | 2010-01-05 | 2018-06-25 |
| A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis CAM-3001, Placebo - Rheumatoid Arthritis | Phase 1 | Completed | MedImmune Ltd | 38 | 2008-10-01 | 2012-07-20 |
Arthritis, Rheumatoid (3) · Inflammatory Bowel Diseases (2) · Asthma (1) · Colitis, Ulcerative (1) · Crohn Disease (1)
mavrilimumab (3) · tralokinumab (2) · MEDI2070 (1) · benralizumab (1)
Poland (5) · Czechia (4) · Germany (4) · Bulgaria (3) · Hungary (3) · Russia (3) · United States (3) · Argentina (2) · Canada (2) · Colombia (2) · Estonia (2) · France (2) · Italy (2) · Spain (2) · Ukraine (2)
Donald Raible, MD (1) · Ehsanollah Esfandiari, PhD MD (1) · Katsuro Yagawa, M.D. (1) · Marius Albulescu (1) · Marius Albulescu, MD (1) · Mark Berner Hansen, MD, PhD (1) · Silvio Danese, MD, PhD (1)
PMID 21613310, PMID 25304132, PMID 25306557, PMID 28213566, PMID 30658649, PMID 38124112